The Alzheimer’s Association is the leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. About us.
Neelum T Aggarwal M.D.
An Associate Professor in the Department of Neurological Sciences at Rush University Medical Center in Chicago and a steering committee member at Alzheimer’s Disease Cooperative Study Group, Dr. Aggarwal, is a cognitive neurologist with particular interest in all types of dementia (Alzheimer’s disease, fronto temporal dementia, vascular dementia and Lewy body dementia). In addition to her active clinical practice, she continues to conduct original research in a variety of large scale community-based studies. She is the co-investigator on multiple grants funded by the National Institute on Aging (NIA). In addition, she is a speaker to many community and business organizations that seek to gain a better understanding of the changes—cognitively and physically—in the aging process, and is an advisor for community-based and minority health initiatives.
Paul S. Aisen M.D.
Paul Aisen, NIA-appointed Director of the Alzheimer’s Disease Cooperative Study and Professor of Neurosciences at the University of California, San Diego, has been conducting therapeutic research on Alzheimer’s disease for the past two decades. Dr. Aisen’s research focuses on inflammatory mechanisms in the brain and the development of new treatment strategies for Alzheimer’s disease and other neurodegenerative diseases. As Director of the ADCS, he collaborates with pharmaceutical companies on drug development and designing and directing multicenter randomized controlled trials to evaluate the safety and efficacy of new treatments. Therapeutic approaches under investigation include secretase modulators, amyloid-binding compounds, cholinesterase inhibitors, nicotine, antioxidants and anti-inflammatory drugs.
Robert Egge is the Alzheimer’s Association’s Chief Public Policy Officer and Executive Director of the Alzheimer’s Impact Movement. Mr. Egge leads the Association’s efforts to elevate Alzheimer’s as a critical federal and state government priority and to implement policies to better serve those affected by Alzheimer’s disease and other dementia. Chief among these priorities are increasing federal funding for Alzheimer’s research and implementing more effective care and support services at the federal and state levels. To read more of Robert Egge’s commentaries, visit his blog page at the Alzheimer’s Impact Movement.
Harry Johns has served as the president and chief executive officer of the Alzheimer’s Association since 2005. Since his arrival, the Alzheimer’s Association has built new momentum for its vision of a world without Alzheimer’s, including the first nationwide campaign to increase understanding and awareness about Alzheimer’s disease, an emphasis on accelerated treatment progress through the promotion of participation in clinical studies, a campaign to enhance early detection of the disease, tools designed to support both individuals with the disease and their caregivers, and targeted research funding to advance diagnosis and treatment. Harry was appointed by the Secretary of Health and Human Services in 2011 to serve as a member of the Advisory Council on Alzheimer’s Research, Care, and Services. He also serves as CEO of the Alzheimer’s Impact Movement and on the Executive Committee of Research!America. Prior to joining the Alzheimer’s Association, he was one of the four members of the executive team of the American Cancer Society.
Michael Rafii, M.D., Ph.D.
Co-Director of the Memory Disorders Clinic at UCSD Perlman Ambulatory Care Center in La Jolla, Assistant Professor of Neurosciences at the University of California, San Diego, and Associate Medical Director of the Alzheimer’s Disease Cooperative Study, Dr. Rafii specializes in cognitive disorders, including dementias such as Alzheimer’s disease. His current research interests include neuroimaging and clinical trials. He received his M.D. and Ph.D. from Brown University and conducted neurogenetics research at Harvard Medical School. Dr. Rafii went on to complete his neurology residency at the Johns Hopkins Hospital and fellowship in Dementia and Cognitive Disorders at the University of California, San Diego.
Sherri Snelling, CEO and founder of the Caregiving Club, is a nationally recognized expert on America’s 65 million family caregivers with special emphasis on how to help caregivers balance “self care” while caring for a loved one. She is the former chairman of the National Alliance for Caregiving and is currently writing a book about celebrities who have been caregivers. She also has served on the caregiving advisory councils for the Centers for Medicare and Medicaid Services (CMS) as well as the Centers for Disease Control (CDC).